The effects of belimumab on synovial inflammation and composition of lymph nodes in SLE patients

The effects of belimumab on synovial inflammation and composition of lymph nodes in SLE patients - Belimumab in SLE synovial inflammation and lymph nodes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51447

Enrollment

Registered

2023-05-22

Start date

2022-03-01

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SLE

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: SLE patients who: 1. fulfill ACR 1997 and/or SLICC and/or ACR/ EULAR 2019 criteria, 2. have active joint disease (arthritis) in wrist, knee or ankle joints. 3. have a SLEDAI-2K score >=6. 4. are aged between 18-75 5. start with belimumab

Exclusion criteria

Exclusion criteria: Patients who are not able to give informed consent. Pregnancy Severe renal impairment (eGFR

Design outcomes

Primary

Measure	Time frame
Differences in lymph node cellular composition and functional aspects in SLE patients starting with belimumab compared to SLE patients starting any other effective treatment.	—

Secondary

Measure	Time frame
Differences in peripheral blood cellular composition and functional aspects in SLE patients starting with belimumab compared to SLE patients starting any other effective treatment.	—

Countries

Netherlands

Outcome results